Multithread effectively and personalize outreach to convert deals faster
Elevate social presence and drive business growth from social media
Identify and prioritize high-intent leads, and improve sales effectiveness
Find and connect with ICP attendees, and improve event outcomes
Alphamab Oncology (江苏康宁杰瑞生物制药有限公司, HKEX: 9966) is a clinical-stage biopharmaceutical company focusing on the research, development, manufacturing, and commercialization of innovative biologics for oncology. Headquartered in Suzhou, China, the company has built a globally competitive proprietary biologics platform in bispecific and multi-specific antibody technology. Its pipeline includes several drug candidates for various cancer indications, with some in late-stage clinical trials or already approved in China, such as Envafolimab (KN035), the world's first subcutaneously administered PD-L1 inhibitor. Alphamab Oncology is committed to addressing unmet medical needs and providing effective cancer treatments to patients worldwide.
The headquarters serves as the core for Alphamab Oncology's R&D, manufacturing, corporate strategy, and administrative operations. It houses advanced laboratories and GMP-compliant production facilities.
State-of-the-art research and development labs, integrated manufacturing facilities capable of producing clinical and commercial-grade biologics, and modern office spaces designed for collaboration and innovation.
A science-driven, innovative, and collaborative work environment. Employees are often highly skilled researchers, scientists, and biopharmaceutical professionals dedicated to advancing cancer therapies. There's a strong emphasis on R&D and achieving breakthroughs.
The Suzhou headquarters is pivotal to Alphamab's strategy, leveraging the rich talent pool, supportive government policies, and robust infrastructure of the Suzhou BioBAY and the broader Yangtze River Delta biopharmaceutical ecosystem.
Alphamab Oncology, while headquartered and with primary operations in China, maintains a global outlook. Its functions supported globally include international clinical trials (e.g., in the US, Australia), strategic partnerships for co-development and commercialization in various regions (e.g., with Pfizer for certain territories), and engagement with international regulatory bodies. The company aims to bring its innovative oncology drugs to patients worldwide.
108 Xinghu Street, Suzhou BioBAY, Suzhou Industrial Park
Suzhou
Jiangsu
China
Address: Specific address not publicly detailed, likely within a major business or research park.
Supports broader clinical trial management across China, facilitates partnerships, and engages with the financial community.
Address: Not publicly specified; operations may be managed through partners or CROs for clinical trials.
To advance its pipeline in the US market and support global drug development programs.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Alphamab Oncology' leadership includes:
Alphamab Oncology has been backed by several prominent investors over the years, including:
Alphamab Oncology has seen some key executive movements aimed at strengthening its clinical development and strategic leadership. Based on available information, there has been at least one notable hire.
Discover the tools Alphamab Oncology uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Alphamab Oncology likely uses common corporate email formats. Based on typical patterns for companies of its nature and region, formats often involve a combination of the employee's first name initial and last name, or full first name and last name.
[firstinitial][lastname]@alphamabonc.com or [firstname].[lastname]@alphamabonc.com
Format
txu@alphamabonc.com (example for Ting Xu if using [firstinitial][lastname])
Example
70%
Success rate
Alphamab Oncology Press Release / HKEX Announcement • 2024-03-27
Alphamab Oncology reported its annual financial results for 2023, detailing significant progress in its clinical pipeline, including advancements for key drug candidates like KN046 and KN026. The company also highlighted the commercial performance of Envafolimab (KN035) and its strategic focus on global expansion....more
Alphamab Oncology Press Release • 2024-02-05
The National Medical Products Administration (NMPA) of China approved Envafolimab (KN035) for the treatment of adult patients with previously treated microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) advanced colorectal cancer. This marks a significant milestone for the drug and patients....more
Alphamab Oncology Press Release • 2023-12-18
Alphamab Oncology announced that its independently developed HER2-bispecific antibody KN026 combined with chemotherapy met the primary endpoint of progression-free survival (PFS) in a Phase III clinical trial as a first-line treatment for HER2-positive gastric or gastroesophageal junction cancer....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Alphamab Oncology, are just a search away.